TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02489786
Drug: patients take 0.25 mg of digoxin daily except thursday and friday
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02489786
Drug: patients take 0.125 mg of digoxin daily
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02489786
Drug: digoxin dose is calculated using Jusko-Koup method and given daily
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03496545
Drug: Bromocriptine 5 MG
Normalized name: bromocriptine 5 MG
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine 5 mg every 4 hours PO/NG/FT
Study: NCT00832572
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
Study: NCT02994225
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery
Study: NCT00209573
Drug: fospropofol disodium
Normalized name: Fospropofol disodium
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02919319
Drug: ACT-541468 (Formulation A)
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
Study: NCT02919319
Drug: ACT-541468 (Formulation B)
Normalized name: Hep B, unspecified formulation
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soft gelatin capsules for oral administration formulated at the strength of 25 mg
Study: NCT02919319
Drug: 14C-labeled ACT-541468
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
Study: NCT01746043
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg by mouth once a day for 6 weeks.
Study: NCT00379522
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
Study: NCT00150579
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02049814
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin tablets
Study: NCT02049814
Drug: Voglibose
Normalized name: Voglibose
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Voglibose tablets
Study: NCT02049814
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose tablets
Study: NCT02084732
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug
Study: NCT01888445
Drug: roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: oral
Study: NCT01888445
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv
Study: NCT02112630
Drug: P-IFN alfa 2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P-IFN alfa 2b 0.75 mcg/kg/week
Study: NCT02112630
Drug: P-IFN alfa 2b
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P-IFN alfa 2a 135 mcg/kg/week
Study: NCT02112630
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg PO once daily or 200 mg PO three times a week
Study: NCT02112630
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg PO three times daily starting at week 4
Study: NCT02857946
Drug: Prevaglip (linagliptin)
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet contains 5 mg linagliptin
Study: NCT02857946
Drug: Trajenta (linagliptin)
Normalized name: Tradjenta
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet contains 5 mg linagliptin
Study: NCT03425084
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
Study: NCT02059499
Drug: imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intra-anally
Study: NCT00092625
Drug: MK0653, ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00092625
Drug: Comparator: ezetimibe, placebo
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00502970
Drug: 16 weeks Interferon Tiw with Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16 weeks Interferon Tiw
Study: NCT00502970
Drug: 24 weeks Interferon
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks Interferon Tiw with Ribavirin
Study: NCT02674958
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
Study: NCT04042688
Drug: intraarticular administration of tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
Study: NCT00006178
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00006178
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00184548
Drug: eptacog alfa (activated)
Normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.
Study: NCT04644705
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
Study: NCT02078440
Drug: Bromocriptine mesylate
Normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
Study: NCT03732482
Drug: Temozolomide capsules
Normalized name: Temozolomide Capsules
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
Study: NCT00669565
Drug: Bavituximab
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
Study: NCT04089904
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
Study: NCT01827267
Drug: neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01827267
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00464451
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Study: NCT00464451
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Study: NCT02942602
Drug: Atorvastatin 20 mg
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study: NCT02942602
Drug: Cholestyramine 8 g
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study: NCT02942602
Drug: Omega-3 2g
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study: NCT02942602
Drug: Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg
Normalized name: atorvastatin / ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study: NCT01809301
Drug: Niaspan
Normalized name: Niaspan
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01732640
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
Study: NCT01732640
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
Study: NCT01732640
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
Study: NCT01732640
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
Study: NCT00005855
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005855
Drug: efaproxiral
Normalized name: EFAPROXIRAL
DrugBank: Efaproxiral (DB08486)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00464646
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
Study: NCT03456804
Drug: ESK981
Normalized name: ESK981
DrugBank: ESK981 (DB18155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
Study: NCT04535869
Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg
Normalized name: sofosbuvir 400 MG
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
Study: NCT02439814
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
Study: NCT02695550
Drug: CT-707
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00464646
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
Study: NCT00464646
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses
Study: NCT00464646
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses
Study: NCT01681680
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given an oral dose of metformin once per day for two days.
Study: NCT00170625
Drug: Hycamtin
Normalized name: Hycamtin
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
Study: NCT01294696
Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s)
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
Study: NCT01265745
Drug: Normal Saline for Injection
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent amounts to subjects weight, once over 120 minutes
Study: NCT02953210
Drug: dexter ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multimodal anesthesia without opioids ketamine as induction drug
Study: NCT02953210
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion intravenous
Study: NCT02953210
Drug: Clonidine Hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clonidine intravenous pre induction
Study: NCT02953210
Drug: Midazolam Hydrochloride
Normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: premedication
Study: NCT02953210
Drug: Isoflurane Volatile Liquid
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintenance of general anesthesia
Study: NCT02953210
Drug: Rocuronium Injectable Solution
Normalized name: rocuronium Injectable Solution
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction of general anesthesia
Study: NCT02953210
Drug: Propofol 1 % Injectable Suspension
Normalized name: propofol 1 % Injectable Suspension
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction of general anesthesia
Study: NCT02953210
Drug: Dexamethasone-21-Sulfobenzoate, Sodium Salt
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: at the end of the procedure 4mg IV
Study: NCT00177060
Drug: hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01261702
Drug: magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
Study: NCT02920697
Drug: S 55746
Normalized name: S-55746
DrugBank: S-55746 (DB18365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
Study: NCT03671174
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg once daily orally
Study: NCT03671174
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg to 200mg twice daily orally
Study: NCT03671174
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg once daily orally
Study: NCT02953210
Drug: Ranitidine Hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at the end of the procedure
Study: NCT02953210
Drug: Ondansetron Hydrochloride
Normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at the end of the procedure
Study: NCT02953210
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at the end of the procedure for infiltration of trocar wounds
Study: NCT03121001
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
Study: NCT03121001
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
Study: NCT03121001
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: loading dose of 15 mg followed by 5 mg per day on day +5
Study: NCT03121001
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g every 8 h (until day 35) will be started on day 5
Study: NCT01624948
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
Study: NCT00384839
Drug: azacitidine for injectable suspension
Normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
Study: NCT00174564
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04195243
Drug: Dapagliflozin Pill
Normalized name: dapagliflozin Pill
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient will take one pill, every 24 hr, during 7 days
Study: NCT04195243
Drug: Empagliflozin Pill
Normalized name: empagliflozin Pill
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient will take one pill, every 24 hr, during 7 days
Study: NCT01359670
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
Study: NCT01359670
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
Study: NCT01293058
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
Study: NCT00760539
Drug: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no